CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 32 enrolled
Drug / intervention
citalopramdrug
Likely dose
citalopram 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01557946
NCT01557946Phase 4Completed
CompareCT.gov

Glutamatergic and GABAergic Mediators of Antidepressant Response in Major Depression

Mclean Hospital·interventional·Posted Mar 20, 2012·Updated Sep 12, 2017

In Brief

A Phase 4 clinical trial evaluating citalopram for MDD and 2 related conditions. Completed, enrolled 32 participants across 1 site.

Detailed Summary

Primarily, this study seeks to evaluate whether citalopram treatment is associated with an increase in the Glutamine (Gln)/Glutamate (Glu) ratio in the anterior cingulate cortex (ACC) from baseline to day 3 of treatment. Additionally, this study would like to examine whether citalopram treatment is associated with an increase in the Gln/Glu ratio in the ACC from baseline to day 7 of treatment. In order to more fully examine baseline neurochemical and functional abnormalities in participants with MDD, we also seek to scan a group of age- and sex-matched non-depressed comparison individuals in order to perform between-group analyses of baseline neuroimaging measures.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMDD, Citalopram, Major Depressive Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 20, 2012
Enrollment StartMar 1, 2012
Primary CompletionSep 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 14.3 years ago

Interventions

citalopramdrug

citalopram 20-40 mg daily